| Tap a line for its trend | Currentlast close | FY25Mar 2025 | FY24Mar 2024 |
|---|
| 21.2 | — | — | |
| 1.2 | 1.2 | 1.3 | |
| 51.8 | 51.8 | 70.8 | |
| 71.8 | — | — | |
| 46.7 | 46.7 | 44.9 | |
| — | +4.0% | — | |
| 20.8 | 20.8 | 21.1 | |
| 44.6% | 44.6% | 47.0% | |
| 11.8 | 11.8 | 11.8 | |
| 7.6 | 7.6 | 2.5 | |
| 16.2% | 16.2% | 5.6% | |
| ₹4.95 | ₹4.95 | ₹1.65 | |
| — | +200.2% | — | |
| 11.8 | 11.8 | 15.8 | |
| −22.3 | −22.3 | −8.0 | |
| −10.4 | −10.4 | 7.9 | |
From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY24 31/03/2024 | FY25 31/03/2025 | Current last close | |
|---|---|---|---|---|
| Market Capitalization | — | — | 21.2 | |
| - Cash, Equiv & ST Investments | 1.3 | 1.2 | 1.2 | |
| + Total Debt | 70.8 | 51.8 | 51.8 | |
| Enterprise Value | — | — | 71.8 | |
| Revenue | 44.9 | 46.7 | 46.7 | |
| Growth %, YoY | — | +4.0 | — | |
| EBITDA | 21.1 | 20.8 | 20.8 | |
| Margin % | 46.98 | 44.56 | 44.56 | |
| EBIT | 11.8 | 11.8 | 11.8 | |
| Net Income | 2.5 | 7.6 | 7.6 | |
| Margin % | 5.62 | 16.22 | 16.22 | |
| EPS, Adj (current shares) | 1.65 | 4.95 | 4.95 | |
| Growth %, YoY | — | +200.2 | — | |
| Cash from Operations | 15.8 | 11.8 | 11.8 | |
| Capital Expenditures | -8.0 | -22.3 | -22.3 | |
| Free Cash Flow | 7.9 | -10.4 | -10.4 | |
Figures from the company's filings with NSE
In FY25 its consolidated net profit was ₹7.6 crore on revenue of ₹46.7 crore. Its debt-to-equity ratio was 0.66 on 31 March 2025.
No. Vivo Bio Tech had borrowings of ₹51.8 crore on 31 March 2025 (consolidated balance sheet), a debt-to-equity ratio of 0.66. Its cash and current investments were ₹1.2 crore, so its net debt was ₹50.6 crore.
Vivo Bio Tech's debt-to-equity ratio was 0.66 on 31 March 2025: borrowings of ₹51.8 crore against total equity of ₹78.2 crore.
Vivo Bio Tech's book value per share was ₹51.12 on 31 March 2025: shareholders' equity of ₹78.2 crore divided by the 1.53 crore shares in issue.
Vivo Bio Tech's net worth — shareholders' equity in its consolidated balance sheet — was ₹78.2 crore on 31 March 2025.
Vivo Bio Tech's basic earnings per share (EPS) were ₹4.95 in FY25, against ₹1.69 in FY24.
In FY25, Vivo Bio Tech generated ₹11.8 crore of cash from operations and spent ₹22.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹10.4 crore. In FY24 it was ₹7.9 crore.
In FY25, Vivo Bio Tech's return on equity (ROE) was 11.4% and its return on capital employed (ROCE) was 11.2%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
In FY25 (April 2024–March 2025), Vivo Bio Tech's consolidated net profit was ₹7.6 crore, up 200.2% from ₹2.5 crore in FY24, on revenue from operations of ₹46.7 crore (up 4.0%).
From Vivo Bio Tech's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
